FLT3 and acute myeloid leukemia: In 2017, midostaurin was approved by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for addition to intensive chemotherapy in patients with newly diagnosed FLT3-mutated AML [1].